logo
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Toronto Star19-07-2025
WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy.
The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the FDA also places future availability of its leading therapy, called Elevidys, in doubt.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US stocks edge higher as a busy week for markets picks up momentum
US stocks edge higher as a busy week for markets picks up momentum

Globe and Mail

time30 minutes ago

  • Globe and Mail

US stocks edge higher as a busy week for markets picks up momentum

NEW YORK (AP) — U.S. stock indexes are ticking higher as a busy week for Wall Street picks up momentum. The S&P 500 was up 0.2% in early trading Tuesday after setting all-time highs for six straight days. The Dow Jones Industrial Average was flat, and the Nasdaq composite was up 0.5%, coming off its own record. JetBlue Airways and SoFi Technologies rose but Merck fell following a jumbled set of profit reports from big U.S. companies. Treasury yields were easing a bit as the Federal Reserve gets set to begin a two-day meeting where it will decide what to do with short-term interest rates. THIS IS A BREAKING NEWS UPDATE. AP's earlier story follows below. Wall Street chugged mostly higher in premarket trading Tuesday as Chinese and U.S. officials begin a second day of trade talks and the Federal Reserve kicks off its two-day meeting to make a decision on interest rate policy. The meetings come amid one of the busiest weeks of corporate earnings season and a flurry of economic data. Futures for the S&P 500 were up 0.2%, while futures for the Dow Jones Industrial Average edged 0.1% higher. Nasdaq futures rose 0.4% before the bell. Analysts said investors were watching for the latest from President Donald Trump and U.S. trade talks with China in Stockholm. U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng were meeting in the Swedish capital. 'Aside from addressing economic imbalances, tariffs are also now well entrenched in the geopolitical arena,' Tan Boon Heng of the Asia & Oceania Treasury Department at Mizuho Bank said in a commentary. With regard to the Fed meeting, the widespread expectation on Wall Street is that officials at the U.S. central bank will wait until September to resume cutting interest rates, though a couple of Trump's appointees could dissent in the vote. The Fed has been on hold with interest rates this year since cutting them several times at the end of 2024. Trump has publicly chastised Fed Chair Jerome Powell for not cutting the benchmark lending rate, which Powell says is due to the uncertain ramifications of Trump's trade war, most notably whether those policies will trigger higher inflation. In corporate news, UnitedHealth Group shares slid 4% after the company badly missed Wall Street's second-quarter earnings expectations and disappointed investors with its updated profit forecast. The health care giant said Tuesday that it expects rising medical costs to continue to pressure its performance and forecast adjusted earnings of at least $16 per share in 2025. The company had started 2025 with an initial forecast for adjusted earnings of up to $30 per share. Union Pacific rose 1.2% in premarket after it offered up details on its bid to merge with Norfolk Southern that would create the U.S.'s first transcontinental railroad. Union Pacific is offering $20 billion cash and one share of its stock to buy Norfolk Southern, the companies said Tuesday, adding that the merger would streamline deliveries of all kinds of raw materials and goods. Norfolk Southern shares fell 3%. Novo Nordisk, which makes the weight loss drug Wegovy, plunged 24% in premarket trading after the company cut its sales and operating profit for the year. Also reporting earnings Tuesday are Boeing and Starbucks. Hundreds of U.S. companies are lined up to report how much profit they made during the spring, with nearly a third of the businesses in the S&P 500 index scheduled to deliver updates this week. The government will also be busy this week, releasing three separate sets of data on the labor market, punctuated with the July jobs report on Friday. The first second-quarter GDP estimate come on Wednesday, followed by the Fed's preferred measure of inflation on Thursday. Elsewhere, in Europe at midday, France's CAC 40 jumped 1.3% in early trading, while the German DAX rose 1.1%. Britain's FTSE 100 added 0.5%. Japan's benchmark Nikkei 225 fell 0.8% to 40,674.55 on broad selling of major companies including automakers and big banks. Toyota Motor Corp. dipped 2.3% and Honda Motor Co. fell 2.1%. Sumitomo Mitsui Financial Group finished 1.8% lower, while Mitsubishi UFJ Financial Group stock dipped 1.6%. Hong Kong's Hang Seng dropped 0.2% to 25,524.45, while the Shanghai Composite gained 0.3% to 3,609.71. Australia's S&P/ASX 200 edged 0.1% higher to 8,704.60. South Korea's Kospi gained 0.7% to 3,230.57. Samsung Electronics edged 0.3% higher after jumping nearly 7% on Monday on news that it signed a deal with Tesla to provide computer chips for its electric vehicles. In energy trading, benchmark U.S. crude was unchanged at $66.71 a barrel. Brent crude, the international standard, gained 5 cents to $69.37 a barrel.

What to know about bladder cancer, which is more common in men, after Deion Sanders revelation
What to know about bladder cancer, which is more common in men, after Deion Sanders revelation

Toronto Sun

timean hour ago

  • Toronto Sun

What to know about bladder cancer, which is more common in men, after Deion Sanders revelation

Smoking is the biggest risk factor for the disease, the American Cancer Society says Published Jul 29, 2025 • Last updated 5 minutes ago • 3 minute read Colorado head coach Deion Sanders considers a question during a news conference to discuss his journey in beating bladder cancer Monday, July 28, 2025, in Boulder, Colo. Photo by AAron Ontiveroz / AP Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the organ and is now considered cured by his doctors, the Pro Football Hall of Famer said Monday. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Sanders said he is upbeat and plans to coach the Buffaloes this fall. Bladder cancer is the 10th leading cause of cancer death in the United States. But recent advancements in its treatment have improved outcomes for people who are diagnosed, according to the American Cancer Society. The 57-year-old Sanders shared the details of his diagnosis and treatment, which involved surgeons reconstructing a section of his intestine to function as a bladder, and said it 'was a fight, but we made it.' Here's what you should know about bladder cancer. What is bladder cancer? This cancer starts when the cells in the bladder, which stores urine, grow out of control and form tumors. In some cases, the cancer spreads to other parts of the body. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. The most common symptom for bladder cancer is blood in the urine, which can cause urine to look orange, pink, or rarely, dark red. The color change can come and go, the American Cancer Society says, and early tumors may not cause pain. Pain or burning while urinating, weak stream, frequent urination or urge to go when the bladder isn't full can also be signs of bladder cancer. Symptoms of advanced bladder cancer can include an inability to urinate, bone pain, loss of appetite, weakness, swollen feet and lower back pain on one side. If you have symptoms, it is worth getting checked out, because all of those symptoms might be from other health issues. Blood in the urine is most often from an infection, a benign tumor, a kidney stone or bladder stone or other benign kidney disease, the American Cancer Society said. This advertisement has not loaded yet, but your article continues below. Sanders said during a news conference on Monday that the cancer was found when he went for a precautionary annual CT scan; he has a history of blood clots in his legs. How common is bladder cancer? Bladder cancer is more common in men than women. The American Cancer Society estimates there will be nearly 85,000 new cases in 2025, with more than 65,000 in men. The incidence rate for bladder cancer has decreased by 1% per year in recent years. Death rates have stayed relatively stable, declining by 1% per year since 2013. What can cause bladder cancer? Smoking is the biggest risk factor, the American Cancer Society said. The recent decline in incidence rates are likely due to fewer people smoking. Other risk factors include working in jobs that expose you to chemicals — like painters, metal and leather workers, miners and firefighters. People who use a urinary catheter for a long time are also at higher risk. This advertisement has not loaded yet, but your article continues below. Read More Outcomes for bladder cancer patients improve based on if and how much the cancer has spread. The five-year relative survival rate is 72% to 97% if the cancer has not spread outside the bladder, but drops to 40% if the cancer has spread to lymph nodes or other nearby parts of the body, and 9% if it has spread further. Treatment can include surgery to remove the tumor, parts of the bladder or the whole bladder; radiation; chemotherapy; targeted drug therapy and immunotherapy. For more health news and content around diseases, conditions, wellness, healthy living, drugs, treatments and more, head to – a member of the Postmedia Network. MLB Sunshine Girls Opinion Toronto & GTA Toronto & GTA

Netherlands bans far-right Israeli ministers as EU considers sanctions over Gaza
Netherlands bans far-right Israeli ministers as EU considers sanctions over Gaza

Toronto Star

timean hour ago

  • Toronto Star

Netherlands bans far-right Israeli ministers as EU considers sanctions over Gaza

THE HAGUE, Netherlands (AP) — The Netherlands has banned two far-right Israeli ministers from entering the country and the European Union has proposed suspending Israel from a lucrative tech investment program as frustration mounts over worsening conditions in Gaza. The ban targets hard-line National Security Minister Itamar Ben-Gvir and Finance Minister Bezalel Smotrich, key partners in Prime Minister Benjamin Netanyahu's coalition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store